Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

@article{Vermorken1999ActiveSI,
  title={Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.},
  author={J. B. Vermorken and Anke M E Claessen and Harm van Tinteren and Helen E. Gall and R Ezinga and Sybren Meijer and Rik J. Scheper and Chris J L M Meijer and Elisabeth Bloemena and Janet H. Ransom and Michael G. Hanna and Herbert M. Pinedo},
  journal={Lancet},
  year={1999},
  volume={353 9150},
  pages={345-50}
}
BACKGROUND Colon cancer is curable by surgery, but cure rate depends on the extent of disease. We investigated whether adjuvant active specific immunotherapy (ASI) with an autologous tumour cell-BCG vaccine with surgical resection was more beneficial than resection alone in stage II and III colon cancer. METHODS In a prospective randomised trial, 254 patients with colon cancer were randomly assigned postoperative ASI or no adjuvant treatment. ASI was three weekly vaccinations starting 4 weeks… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS